Skip to content

Dostinex versus Quinagolide for prevention of ovarian hyperstimulation syndrome

Randomaized clinical trial to compare Dostinex versus Quinagolide to prevention of ovarian hyperstimulation syndrome

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016053128187N1
Enrollment
126
Registered
2017-03-04
Start date
2016-12-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrom. Hyperstimulation of ovaries

Interventions

Intervention 1: The first group treat with 0.5mg of Dostinex every day for seven days commencing on the day of oocyte retrival. Intervention 2: The second group treat with 75 mg of Quinagolid every
Treatment - Drugs
The first group treat with 0.5mg of Dostinex every day for seven days commencing on the day of oocyte retrival.
The second group treat with 75 mg of Quinagolid every day for 7 days commencing on the day of oocyte retrival.

Sponsors

Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 20-40 years old patient; 20 oocytes when agonist GnRh start;risk of OHSS Exclusion criteria: metabolic dysfunction; hypertension; history of syncope; heart disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Nausea and vomiting. Timepoint: 3 and 6 days after drug prescription. Method of measurement: Questionnaire.;Abdominal distention. Timepoint: 3 and 6 days after drug prescription. Method of measurement: Questionnaire and physical examination.;Hemoconcentration. Timepoint: 3 and 6 days after drug prescription. Method of measurement: Clinical lab.;Ascit. Timepoint: 3 and 6 days after drug prescription. Method of measurement: Sonography.

Secondary

MeasureTime frame
Tap of ascit. Timepoint: 3 and 6 days after drug prescription. Method of measurement: paracentesis.;Hospitalization. Timepoint: 3 and 6 days after drug prescription. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Sadeghzadeh

Infertility & Reproductive Health Research Center,Shahid Beheshti University of Medical Sciences

irhrc@yahoo.com+98 21 2271 2234

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026